Barclays Maintains Astrana Health(ASTH.US) With Buy Rating, Maintains Target Price $53
Barclays analyst Andrew Mok CFA maintains $Astrana Health(ASTH.US)$ with a buy rating, and maintains the target price at $53.According to TipRanks data, the analyst has a success rate of 53.2% and a
Barclays Sticks to Their Buy Rating for Astrana Health (ASTH)
Truist Financial Maintains Astrana Health(ASTH.US) With Buy Rating, Maintains Target Price $55
Truist Financial analyst Jailendra Singh maintains $Astrana Health(ASTH.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 42.7
Truist Securities Adjusts Price Target on Astrana Health to $55 From $47, Keeps Buy Rating
Astrana Health (ASTH) has an average rating of buy and mean price target of $50.50, according to analysts polled by FactSet.
Astrana Health Earnings Call Highlights Growth and AI Edge
Astrana Health | 10-Q: Q2 2026 Earnings Report
Truist Financial Maintains Astrana Health(ASTH.US) With Buy Rating, Announces Target Price $55
Truist Financial analyst Jailendra Singh maintains $Astrana Health(ASTH.US)$ with a buy rating, and sets the target price at $55.According to TipRanks data, the analyst has a success rate of 42.2%
Results: Astrana Health, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Last week saw the newest second-quarter earnings release from Astrana Health, Inc. (NASDAQ:ASTH), an important milestone in the company's journey to build a stronger business. It looks like a
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)
A Quick Look at Today's Ratings for Astrana Health(ASTH.US), With a Forecast Between $41 to $53
On Aug 07, major Wall Street analysts update their ratings for $Astrana Health(ASTH.US)$, with price targets ranging from $41 to $53.Barclays analyst Andrew Mok CFA maintains with a buy rating, and
Analysts' Opinions Are Mixed on These Healthcare Stocks: Astrana Health (ASTH), Hyperfine (HYPR) and Organogenesis Holdings (ORGO)
Barclays Maintains Overweight on Astrana Health, Raises Price Target to $53
Barclays analyst Andrew Mok maintains Astrana Health (NASDAQ:ASTH) with a Overweight and raises the price target from $50 to $53.
Analysts Conflicted on These Healthcare Names: Astrana Health (ASTH), Resmed (RMD) and Definium Therapeutics (DFTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astrana Health (ASTH) and ALX Oncology Holdings (ALXO)
Express News | Astrana Health Inc Outlook Q3 Revenue USD 1,000-1,030 Million
Earnings Flash (ASTH) Astrana Health, Inc. Posts Q2 Adjusted EPS $0.80 per Share, Vs. FactSet Est of $0.79
04:29 PM EDT, 08/06/2026 (MT Newswires) -- Earnings Flash (ASTH) Astrana Health, Inc. Posts Q2 Adjusted EPS $0.80 per Share, vs. FactSet Est of $0.79
Earnings Flash (ASTH) Astrana Health, Inc. Reports Q2 Revenue $972.5M, Vs. FactSet Est of $985.6M
04:28 PM EDT, 08/06/2026 (MT Newswires) -- Earnings Flash (ASTH) Astrana Health, Inc. Reports Q2 Revenue $972.5M, vs. FactSet Est of $985.6
Astrana Health Sees Q3 Sales $1.000B-$1.030B Vs $1.021B Est
Astrana Health (NASDAQ:ASTH) sees Q3 sales of $1.000 billion-$1.030 billion vs $1.021 billion analyst estimate.
Astrana Health Affirms FY2026 Sales Guidance of $3.800B-$4.100B Vs $4.001B Est
Astrana Health (NASDAQ:ASTH) affirms FY2026 sales outlook from $3.800 billion-$4.100 billion to $3.800 billion-$4.100 billion vs $4.001 billion estimate.
Astrana Health | 8-K: Astrana Health, Inc. Reports Second Quarter 2026 Results Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET